21 May 2026
Lilly’s retatrutide achieves up to 30% weight loss in Phase 3 TRIUMPH-1
Phase 3 TRIUMPH-1: three doses met endpoints at 80 weeks with dose-related, substantial weight loss. 104-week extension in BMI≥35 showed further loss; cardiometabolic markers improved; GI AEs common.
